490 related articles for article (PubMed ID: 30236647)
21. Enhancement of Therapies for Glioblastoma (GBM) Using Nanoparticle-based Delivery Systems.
Wiwatchaitawee K; Quarterman JC; Geary SM; Salem AK
AAPS PharmSciTech; 2021 Feb; 22(2):71. PubMed ID: 33575970
[TBL] [Abstract][Full Text] [Related]
22. Nanostructured Therapeutic Systems of PUFAs for the Treatment of Glioblastoma Multiforme.
Saad S; Beg S; Jain GK; Ahmad FJ
Curr Drug Metab; 2021; 22(14):1087-1102. PubMed ID: 33388016
[TBL] [Abstract][Full Text] [Related]
23. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.
Agarwal S; Sane R; Oberoi R; Ohlfest JR; Elmquist WF
Expert Rev Mol Med; 2011 May; 13():e17. PubMed ID: 21676290
[TBL] [Abstract][Full Text] [Related]
24. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data.
Sarkaria JN; Hu LS; Parney IF; Pafundi DH; Brinkmann DH; Laack NN; Giannini C; Burns TC; Kizilbash SH; Laramy JK; Swanson KR; Kaufmann TJ; Brown PD; Agar NYR; Galanis E; Buckner JC; Elmquist WF
Neuro Oncol; 2018 Jan; 20(2):184-191. PubMed ID: 29016900
[TBL] [Abstract][Full Text] [Related]
25. Bioscaffold-based study of glioblastoma cell behavior and drug delivery for tumor therapy.
Tran K; Brice R; Yao L
Neurochem Int; 2021 Jul; 147():105049. PubMed ID: 33945833
[TBL] [Abstract][Full Text] [Related]
26. Nanoparticles: Novel vehicles in treatment of Glioblastoma.
Pourgholi F; Hajivalili M; Farhad JN; Kafil HS; Yousefi M
Biomed Pharmacother; 2016 Feb; 77():98-107. PubMed ID: 26796272
[TBL] [Abstract][Full Text] [Related]
27. Multi-ligand functionalized blood-to-tumor sequential targeting strategies in the field of glioblastoma nanomedicine.
Martins C; Sarmento B
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(5):e1893. PubMed ID: 37186374
[TBL] [Abstract][Full Text] [Related]
28. Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment.
Li TF; Li K; Wang C; Liu X; Wen Y; Xu YH; Zhang Q; Zhao QY; Shao M; Li YZ; Han M; Komatsu N; Zhao L; Chen X
J Control Release; 2017 Dec; 268():128-146. PubMed ID: 29051064
[TBL] [Abstract][Full Text] [Related]
29. Blood-brain barrier, cytotoxic chemotherapies and glioblastoma.
Dréan A; Goldwirt L; Verreault M; Canney M; Schmitt C; Guehennec J; Delattre JY; Carpentier A; Idbaih A
Expert Rev Neurother; 2016 Nov; 16(11):1285-1300. PubMed ID: 27310463
[TBL] [Abstract][Full Text] [Related]
30. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
[TBL] [Abstract][Full Text] [Related]
31. Delivering Therapeutics to Glioblastoma: Overcoming Biological Constraints.
Mathew EN; Berry BC; Yang HW; Carroll RS; Johnson MD
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163633
[TBL] [Abstract][Full Text] [Related]
32. Intraarterial drug delivery for glioblastoma mutiforme: Will the phoenix rise again?
Joshi S; Ellis JA; Ornstein E; Bruce JN
J Neurooncol; 2015 Sep; 124(3):333-43. PubMed ID: 26108656
[TBL] [Abstract][Full Text] [Related]
33. A Combined Approach Employing Chlorotoxin-Nanovectors and Low Dose Radiation To Reach Infiltrating Tumor Niches in Glioblastoma.
Tamborini M; Locatelli E; Rasile M; Monaco I; Rodighiero S; Corradini I; Franchini MC; Passoni L; Matteoli M
ACS Nano; 2016 Feb; 10(2):2509-20. PubMed ID: 26745323
[TBL] [Abstract][Full Text] [Related]
34. Brain-targeted Nano-architectures for Efficient Drug Delivery and Sensitization in Glioblastoma.
Ravuluri JAV; Rao V; Kumar G; Manandhar S; Cheruku SP; Bisht P; Chamallmudi MR; Nandakumar K; Kumar L; Kumar N
Curr Pharm Des; 2023; 29(22):1775-1790. PubMed ID: 37403389
[TBL] [Abstract][Full Text] [Related]
35. Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma.
Oberoi RK; Parrish KE; Sio TT; Mittapalli RK; Elmquist WF; Sarkaria JN
Neuro Oncol; 2016 Jan; 18(1):27-36. PubMed ID: 26359209
[TBL] [Abstract][Full Text] [Related]
36. Targeting glioblastoma through nano- and micro-particle-mediated immune modulation.
Poot E; Maguregui A; Brunton VG; Sieger D; Hulme AN
Bioorg Med Chem; 2022 Oct; 72():116913. PubMed ID: 36007293
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma.
Gabelloni P; Da Pozzo E; Bendinelli S; Costa B; Nuti E; Casalini F; Orlandini E; Da Settimo F; Rossello A; Martini C
Neuroscience; 2010 Jun; 168(2):514-22. PubMed ID: 20382206
[TBL] [Abstract][Full Text] [Related]
38. Recent advances in targeted drug delivery for the treatment of glioblastoma.
Mao M; Wu Y; He Q
Nanoscale; 2024 May; 16(18):8689-8707. PubMed ID: 38606460
[TBL] [Abstract][Full Text] [Related]
39.
Gallego L; Ceña V
Expert Opin Drug Deliv; 2020 Nov; 17(11):1541-1554. PubMed ID: 32791861
[TBL] [Abstract][Full Text] [Related]
40. Design of Biopolymer-Based Interstitial Therapies for the Treatment of Glioblastoma.
Pena ES; Graham-Gurysh EG; Bachelder EM; Ainslie KM
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
